Method for producing mixed powder, mixed powder, powder, and powder culture medium
By dissolving and drying cystine with tryptophan, threonine and serine, the problems of insufficient solubility and liquid alkalinity of the cystine mixed powder are solved, and cystine is realized It has high solubility and stability at a pH, and is suitable for the production of powders of insoluble cystine.
Patent Information
- Application Number
- CN202380028298.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-29
- Publication Date
- 2024-11-05
AI Technical Summary
The mixed powder prepared by insoluble cystine is insufficiently soluble after freeze-drying, and the liquid becomes alkaline when dissolved in water, resulting in the possibility of decomposition of vitamins and other components, which has problems with solubility and stability.
The mixture powder is prepared by using tryptophan, threonine and serine as the second component and by drying it, and the temperature and pH in the dissolution process are controlled, and spray drying or heating and reduced pressure drying methods are used. Ensure that the pH of the powder when dissolved in water is within the range of 6.0 to 8.5.
The high solubility and stability of cystine are achieved, the powder is dissolved within the neutral pH range, the component decomposition is avoided, and the solubility and application value of the mixed powder are improved.
Smart Images

Figure BDA0005047017940000111 
Figure BDA0005047017940000121 
Figure BDA0005047017940000131
Abstract
Description
Technical Field
[0001] The invention relates to a method for manufacturing a mixed powder, the mixed powder, the powder and a powder culture medium. Background Art
[0002] Conventionally, in order to improve the solubility of a poorly soluble culture medium, a method of preparing an aqueous solution together with other components and then freeze-drying the solution has been proposed (Patent Document 1).
[0003] Previous technical literature
[0004] Patent Literature
[0005] Patent Document 1: Japanese Patent Application No. 2018-521682 Summary of the invention
[0006] Technical issues to be solved by the invention
[0007] Among them, the present inventors prepared an aqueous solution of poorly soluble cystine with other components (hereinafter, also referred to as "second component") and then freeze-dried it, and it was clarified that the solubility of the obtained mixed powder was insufficient depending on the type of the second component. In addition, it was clarified that the liquid property of the obtained mixed powder when dissolved in water became alkaline depending on the type of the second component. If the liquid property becomes alkaline, it may decompose when components such as vitamins are present in the culture medium, so there is a problem.
[0008] Therefore, in view of the above-mentioned actual situation, an object of the present invention is to provide a method for producing a powder, the powder and a powder culture medium containing the powder, wherein the method for producing a powder is used to obtain a powder having excellent solubility for poorly soluble cystine and having a neutral liquid property (pH 6.0 to 8.5) when dissolved in water.
[0009] Means for solving technical problems
[0010] The present inventors have conducted intensive studies on the above-mentioned problems and, as a result, have found that the above-mentioned problems can be solved by using at least one component selected from the group consisting of tryptophan, threonine and serine as the second component, thereby completing the present invention.
[0011] That is, the present inventors have found that the above-mentioned problems can be solved by the following configuration.
[0012] (1) A method for producing a mixed powder, comprising the following steps: a dissolving step of dissolving cystine and at least one specific component selected from the group consisting of tryptophan, threonine and serine in a solvent to obtain a solution containing cystine and the specific component; and a powdering step of drying the solution to obtain a mixed powder of cystine and the specific component.
[0013] (2) The method for producing a mixed powder according to (1) above, wherein in the dissolving step, heating and / or alkali are used for dissolving.
[0014] (3) The method for producing a mixed powder according to (1) or (2) above, wherein heating is used for dissolving in the dissolving step.
[0015] (4) The method for producing a mixed powder according to any one of (1) to (3) above, wherein the pulverization step is a step of drying the solution by spray drying and / or a step of drying the solution by heating and reducing pressure.
[0016] (5) The method for producing a mixed powder according to any one of (1) to (4) above, wherein in the dissolving step, a mixing ratio of the specific component to cystine is 1 to 10 in terms of mass ratio.
[0017] (6) A mixed powder produced by the method for producing a mixed powder according to any one of (1) to (5) above.
[0018] (7) A mixed powder comprising cystine and at least one specific component selected from the group consisting of tryptophan, threonine and serine, wherein when the mixed powder is dissolved in water at 15 to 25° C. for 7 minutes, the pH of the resulting solution is 6.0 to 8.5, and the cystine concentration in the resulting solution is 0.12 g / L or more.
[0019] (8) A powder comprising cystine and at least one specific component selected from the group consisting of tryptophan, threonine and serine, wherein the powder satisfies the following conditions when dissolved in water so that the final concentration of cystine is 0.14 g / L or more when the cystine is completely dissolved at 15 to 25°C.
[0020] Conditions: The time for adding water in an amount sufficient to achieve the final concentration was set to 0 minutes, and the liquid was taken out after 7 minutes and filtered through a 0.2 μm filter. The pH of the liquid was 8.5 or less, and the cystine contained was 0.12 g / L or more.
[0021] (9) A powder culture medium comprising the mixed powder or the powder according to any one of (6) to (8) above.
[0022] Effects of the Invention
[0023] As described below, the present invention can provide a method for producing a powder having excellent solubility for poorly soluble cystine and having a neutral liquid property (pH 6.0 to 8.5) when dissolved in water, the powder, and a powder culture medium containing the powder. DETAILED DESCRIPTION
[0024] Hereinafter, the method for producing the mixed powder of the present invention and the mixed powder of the present invention will be described.
[0025] In addition, in this specification, the numerical range expressed using "to" means a range including the numerical values described before and after "to" as the lower limit and the upper limit.
[0026] In addition, each component may be used alone or in combination of two or more. Here, when two or more components are used in combination, the content of the component refers to the total content unless otherwise specified.
[0027] [1] Method for producing mixed powder
[0028] The method for producing a mixed powder of the present invention (hereinafter, also referred to as "the production method of the present invention") comprises the following steps:
[0029] a dissolving step of dissolving cystine and at least one specific component selected from the group consisting of tryptophan, threonine, and serine in a solvent to obtain a solution containing cystine and the specific component; and
[0030] In the powdering step, the solution is dried to obtain a mixed powder of cystine and the specific component.
[0031] The manufacturing method of the present invention adopts such a structure, and therefore it is considered that the above-mentioned problems can be solved. The reason is not clear, but it is considered to be roughly as follows.
[0032] As one of the main factors of the poor solubility of cystine, it is believed that the aggregation of the hydrophobic part between the molecules of cystine. In contrast, in the present invention, cystine and the specific component are dissolved in a solvent and then dried, so it is believed that the specific component enters between the molecules of cystine, suppresses the hydrophobic part formed by the aggregation between the molecules of cystine, and easily allows the solvent (especially hydrophilic solvent) to penetrate. Moreover, the specific component shows excellent solubility. Therefore, according to the present invention, it is believed that a powder mixed at the molecular level with cystine and a specific component with high solubility can be obtained. As a result, it is believed that the mixed powder obtained by the manufacture method of the present invention shows excellent solubility. This can also be inferred from the fact that simply mixing cystine and the specific component will not improve the solubility.
[0033] Hereinafter, each step of the production method of the present invention will be described.
[0034] [Dissolution process]
[0035] The dissolving step is a step of dissolving cystine and the specific component in a solvent to obtain a solution containing cystine and the specific component.
[0036] 〔Cystine〕
[0037] The mixing amount of cystine relative to the solvent is not particularly limited, but from the reason that the effect of the present invention is more excellent, when heating is used for dissolution, it is preferably 0.01 to 100 g / L, more preferably 0.05 to 10 g / L, and further preferably 0.1 to 2 g / L. When an alkali is used for dissolution, it is preferably 0.1 to 1000 g / L, more preferably 1 to 200 g / L, and further preferably 10 to 100 g / L.
[0038] 〔Specific ingredients〕
[0039] The specific component is at least one selected from the group consisting of tryptophan, threonine, and serine. From the perspective of achieving a more excellent effect of the present invention, the specific component is preferably threonine or serine, and more preferably threonine.
[0040] The mixing amount of the specific component relative to the solvent is not particularly limited, but from the reason that the effect of the present invention is more excellent, when heating is used for dissolution, it is preferably 0.01 to 1000 g / L, more preferably 0.1 to 100 g / L, and further preferably 1 to 5 g / L. When an alkali is used for dissolution, it is preferably 1 to 3000 g / L, more preferably 10 to 2000 g / L, and further preferably 100 to 1000 g / L.
[0041] 〔Mixing ratio〕
[0042] From the reason that the effect of the present invention is more excellent, the mixing ratio of the specific component to cystine (mixing amount of the specific component / mixing amount of cystine) is preferably 0.1 to 100 in terms of mass ratio, more preferably 0.5 to 80, further preferably 1 to 60, particularly preferably 2 to 40, and most preferably 5 to 20. In addition, hereinafter, the mixing ratio of the second component to cystine (mixing amount of the second component / mixing amount of cystine) (mass ratio) is also simply referred to as "mixing ratio".
[0043] 〔Solvent〕
[0044] The solvent used in the dissolving step is not particularly limited, but water or a hydrophilic solvent is preferred, and water is more preferred, because the effect of the present invention is more excellent. Furthermore, the solvent may be liquefied when heated, and may be solid at room temperature.
[0045] The hydrophilic solvent is not particularly limited as long as it is a hydrophilic solvent. Specific examples thereof include compounds containing ether groups such as tetrahydrofuran, dimethoxyethane, diethylene glycol dimethyl ether, and polyethylene glycol dialkyl ethers; compounds containing lactone groups such as γ-butyrolactone and γ-valerolactone; caprolactam, N-methylcaprolactam, N,N-dimethylacetamide, N-methylacetamide, N,N-dimethylformamide (DMF), N-methylformamide, N-methylformanilide, N-methylpyrrolidone (NM P), compounds containing amide or lactam groups such as N-octylpyrrolidone and pyrrolidone; sulfones and sulfoxides such as cyclopentane (tetramethylene sulfone) and dimethyl sulfoxide (DMSO); sugars or sugar derivatives such as sucrose, glucose, fructose and lactose; sugar alcohols such as sorbitol and mannitol; furan derivatives such as 2-furancarboxylic acid and 3-furancarboxylic acid; alcohols such as methanol, ethylene glycol, glycerol, diethylene glycol and triethylene glycol; phenol compounds such as dimethoxyphenol, m-cresol, o-cresol, p-cresol, phenol and naphthol. These hydrophilic solvents may be used alone or in combination of two or more.
[0046] 〔Dissolution method〕
[0047] The method of dissolving cystine and the specific component in the solvent is not particularly limited, but for the reason that the effect of the present invention is more excellent, preferably heating and / or alkali are used, and more preferably heating is used. In addition, "using heating" means heating the solvent, and "using alkali" means adding alkali (sodium hydroxide, etc.) to the solvent.
[0048] The temperature for heating during dissolution is not particularly limited, but is preferably 40 to 300° C., preferably 40 to 200° C., and more preferably 60 to 90° C. for the purpose of achieving the best effect of the present invention. During dissolution, the solvent may be at or above the boiling point and may be in a subcritical or supercritical state under pressure.
[0049] When an alkali is used in the dissolution, the pH of the solution is preferably 12 or more because the effect of the present invention is more excellent. Also, when an alkali is used in the dissolution, the pH is preferably adjusted to neutral using an acid (hydrochloric acid, etc.) after the dissolution (neutralization step) because the effect of the present invention is more excellent. In addition, in this specification, neutral means pH 6.0 to 8.5.
[0050] When an alkali is used for dissolution and then an acid is used to adjust the pH to neutral, the resulting solution contains salt. It is believed that when the solution contains salt, the inhibition of the molecular association of cystine by a specific component is slightly reduced. In addition, when the solution contains salt, the resulting mixed powder also contains salt. When the mixed powder contains salt, the osmotic pressure may increase when dissolved in water. For this reason, it is more preferable to use heating than alkali during dissolution.
[0051] [Powderization process]
[0052] The powdering step is a step of drying the solution obtained in the above-mentioned dissolving step to obtain a mixed powder of cystine and a specific component.
[0053] 〔Drying method〕
[0054] The method for drying the solution is not particularly limited, and specific examples thereof include spray-drying, drying by heating (e.g., 40 to 80° C.) and reduced pressure (e.g., 100 mmHg or less) (e.g., drying using an evaporator), and freeze-drying.
[0055] The method for drying the solution is preferably a drying method other than freeze drying, more preferably spray drying and / or drying by heating and reduced pressure, and even more preferably spray drying, from the perspectives of high uniformity of the obtained mixed powder, resulting in better solubility and short drying time.
[0056] [Mixed powder]
[0057] The mixed powder obtained by the production method of the present invention is particularly useful as a powder for a culture medium.
[0058] [2] Mixed powder
[0059] The mixed powder of the present invention is a mixed powder of cystine and at least one specific component selected from the group consisting of tryptophan, threonine and serine, wherein when dissolved in water at 15 to 30° C. (preferably 15 to 25° C.) for 7 minutes, the pH of the obtained aqueous solution is 6.0 to 8.5, and the cystine concentration in the obtained solution is 0.12 g / L or more.
[0060] The cystine concentration is preferably 0.12 g / L to 0.5 g / L, more preferably 0.13 g / L to 0.4 g / L, and most preferably 0.15 g / L to 0.3 g / L.
[0061] The mixed powder is preferably a mixed powder obtained by the production method of the present invention.
[0062] Example
[0063] Hereinafter, the present invention will be described in further detail with reference to Examples, but the present invention is not limited thereto.
[0064] [Manufacturing of powder]
[0065] Each powder was produced as follows.
[0066] [Example 1]
[0067] <Dissolving process>
[0068] 500 mL of distilled water, 80 mg of L-cystine (0.33 mmol, manufactured by FUJIFILM Wako Pure Chemical Corporation), and 240 mg of L-tryptophan (1.17 mmol, manufactured by FUJIFILM Wako Pure Chemical Corporation) were added to a 1000 mL three-necked flask equipped with a stirring blade, and the mixture was heated at 80° C. for 2 hours while being stirred at 300 rpm (revolutions / minute), and complete dissolution was confirmed. In this way, a supersaturated solution was obtained. The obtained supersaturated solution is also referred to as A1. Even when returned to room temperature, A1 is stable for about several hours.
[0069] <Powdering process>
[0070] The supersaturated solution (A1) obtained in the dissolution step was placed in a 1000 mL flask. Then, it was dried by heating (50 to 60° C.) and reducing pressure (50 mmHg or less) using an evaporator. In this way, a powder was obtained. The obtained powder is also referred to as CT1.
[0071] For CT1, use 1 The composition was confirmed by H-NMR (nuclear magnetic resonance) method, and the result was that it was a mixed powder with cystine:tryptophan=1:3.5 (molar ratio).
[0072] [Examples 2-3]
[0073] A mixed powder of cystine and tryptophan was obtained by the same procedure as in Example 1 except that the mixing amount of L-tryptophan in the dissolution step was changed as described in Table 1.
[0074] [Example 4]
[0075] In the powdering step, the supersaturated liquid obtained in the dissolving step was spray-dried using a small spray dryer B-290 (manufactured by Buchi Co., Ltd.), and a mixed powder of cystine and tryptophan was obtained in the same manner as in Example 1. In addition, when the supersaturated liquid was insufficient when the powder was obtained, additional supersaturated liquid was prepared for use.
[0076] [Examples 5-6]
[0077] A mixed powder of cystine and tryptophan was obtained by following the same procedure as in Example 4 except that the mixing amount of L-tryptophan in the dissolution step was changed as described in Table 1.
[0078] [Example 7]
[0079] In the powdering step, a mixed powder of cystine and tryptophan was obtained by the same procedure as in Example 1 except that the supersaturated solution obtained in the dissolution step was freeze-dried for 1 week using a freeze dryer FDU-12AS (manufactured by AS ONE CORPORATION) to obtain a powder.
[0080] [Example 8]
[0081] Except that the mixing amount of L-tryptophan in the dissolving step was changed as described in Table 1, the same procedure as in Example 7 was followed to obtain a mixed powder of cystine and tryptophan.
[0082] [Example 9]
[0083] <Dissolving process>
[0084] 30 mL of distilled water, 2.0 g of L-cystine (8.32 mmol, manufactured by FUJIFILM Wako Pure Chemical Corporation), 6.0 g of L-tryptophan (29.3 mmol), and 4.23 g of sodium hydroxide (manufactured by FUJIFILM Wako Pure Chemical Corporation) were added to a 100 mL beaker to make the pH above 12 and temporarily completely dissolve. Then, a 5N (normal concentration) HCl aqueous solution (manufactured by FUJIFILM Wako Pure Chemical Corporation) was added to adjust the pH to between 7 and 8. A slurry was thus obtained. The obtained slurry is also referred to as NA1.
[0085] <Powdering process>
[0086] The slurry (NA1) obtained in the dissolution step was placed in a 1000 mL flask. Then, it was dried by heating (50-60°C) and reducing pressure (below 50 mmHg) using an evaporator. In this way, a powder was obtained. The obtained powder is also called CT9. For CT9, use 1 The composition was confirmed by H-NMR method, and the result was a mixed powder with cystine:tryptophan=1:3.5 (molar ratio).
[0087] [Examples 10-11]
[0088] A mixed powder of cystine and tryptophan was obtained by following the same procedure as in Example 9 except that the mixing amount of L-tryptophan in the dissolution step was changed as described in Table 1.
[0089] [Example 12]
[0090] In the powdering step, a mixed powder of cystine and tryptophan was obtained by the same procedure as in Example 9 except that the slurry obtained in the dissolving step was freeze-dried for one week using a freeze dryer FDU-12AS (manufactured by AS ONE CORPORATION) to obtain a powder.
[0091] [Examples 13-14]
[0092] A mixed powder of cystine and tryptophan was obtained by the same procedure as in Example 12 except that the mixing amount of L-tryptophan in the dissolution step was changed as described in Table 1.
[0093] [Examples 15 to 28]
[0094] A mixed powder of cystine and serine was obtained by the same procedures as in Examples 1 to 14 except that L-serine was used instead of L-tryptophan in the dissolution step.
[0095] [Examples 29 to 42]
[0096] A mixed powder of cystine and threonine was obtained by the same procedures as in Examples 1 to 14 except that L-threonine was used instead of L-tryptophan in the dissolution step.
[0097] [Comparative Example 1]
[0098] <Dissolving process>
[0099] 500 mL of distilled water and 80 mg of L-cystine (0.33 mmol, manufactured by FUJIFILM Wako Pure Chemical Corporation) were added to a 1000 mL three-necked flask equipped with a stirring blade, and the mixture was heated at 80° C. for 2 hours while being stirred at 300 rpm. Complete dissolution was confirmed. In this way, a supersaturated solution was obtained. The obtained supersaturated solution is also referred to as D1.
[0100] <Powdering process>
[0101] The supersaturated solution (D1) obtained in the dissolution step was placed in a 1000 mL flask. Then, it was dried by heating (70° C.) and reducing pressure (50 mmHg or less) using an evaporator. In this way, a powder was obtained. The obtained powder is also referred to as CH1.
[0102] [Comparative Example 2]
[0103] As the powder of Comparative Example 2, L-cystine (manufactured by FUJIFILM Wako Pure Chemical Corporation) was used.
[0104] [Comparative Example 3]
[0105] A powder was obtained by the same procedure as in Example 1 except that L-phenylalanine was used instead of L-tryptophan in the dissolving step. The obtained powder is also referred to as CH2.
[0106] For CH2, use 1 The composition was confirmed by H-NMR method, and the result was a mixed powder with cystine:phenylalanine=1:6.9 (molar ratio).
[0107] [Comparative Example 4]
[0108] A powder was obtained by the same procedure as in Example 1 except that L-arginine was used instead of L-tryptophan in the dissolution step. The obtained powder is also referred to as CH3.
[0109] For CH3, use 1 The composition was confirmed by H-NMR method, and the result was a mixed powder with cystine:arginine=1:6.9 (molar ratio).
[0110] [evaluate]
[0111] The following evaluations were performed on each of the obtained powders.
[0112] 〔Solubility〕
[0113] 30 mL of distilled water was added to a 100 mL beaker, and the obtained powder (25° C.) was added while stirring with a stirring bar. The amount of powder added was as described in the "Amount Added" column in Tables 1 to 3. The addition time was set to 0 minutes, and the solubility was visually evaluated according to the following evaluation criteria.
[0114] The results are shown in Tables 1 to 3. In practical terms, AA, A, B, C or D is preferred, AA, A, B or C is more preferred, AA, A or B is further preferred, AA or A is particularly preferred, and AA is most preferred.
[0115] The above-mentioned addition amount was calculated based on the mixing ratio so that the amount of cystine in the solution would be 0.17 g / L.
[0116] AA: Completely dissolved within 30 seconds
[0117] A: Completely dissolved in more than 30 seconds and less than 5 minutes
[0118] B: Completely dissolved in more than 5 minutes and less than 10 minutes
[0119] C: Completely dissolved in more than 10 minutes and less than 15 minutes
[0120] D: Completely dissolved in more than 15 minutes and less than 1 hour
[0121] E: Even after more than 1 hour, there is still white turbidity and sediment
[0122] 〔Liquidity〕
[0123] The pH of the solution obtained in the evaluation of solubility was evaluated. Then, the liquid property was evaluated according to the following evaluation criteria. The results are shown in Tables 1 to 3. In practical terms, neutrality is preferred.
[0124] Acidity: pH less than 6.0
[0125] Neutral: pH 6.0 to 8.5
[0126] Alkaline: pH over 8.5
[0127] 〔Comprehensive evaluation〕
[0128] Based on the evaluation results of solubility and liquid property, comprehensive evaluation was performed according to the following evaluation criteria. The results are shown in Tables 1 to 3.
[0129] AA: Dissolves completely within 30 seconds, and the liquid is neutral.
[0130] A: Completely dissolved within 5 minutes, liquid is neutral
[0131] B: Completely dissolved within 10 minutes, liquid is neutral
[0132] C: Completely dissolved within 15 minutes, liquid is neutral.
[0133] D: Completely dissolved within 1 hour, liquid is neutral.
[0134] E: Still cloudy after 1 hour and / or pH is not neutral.
[0135]
[0136]
[0137]
[0138] In Tables 1 to 3, the "composition ratio (molar ratio)" of the powder indicates the composition ratio (molar ratio) of the second component to cystine. The composition ratio is calculated using 1 Confirmed by H-NMR method.
[0139] In Tables 1 to 3, the "salt content" of the powder indicates the amount (mass %) of the salt (NaCl) when the total of cystine and the second component is taken as 100 mass %.
[0140] [Summary of the table]
[0141] As can be seen from Tables 1 to 3, the mixed powders obtained by the production method of the present invention, i.e., Examples 1 to 42, showed excellent solubility compared to a powder obtained by dissolving only cystine in a solvent and drying it (Comparative Example 1), commercially available cystine (Comparative Example 2), and a mixed powder obtained by using phenylalanine instead of a specific component (Comparative Example 3). In addition, Comparative Examples 1 to 2 did not completely dissolve within 4 hours. Comparative Example 3 was almost not dissolved.
[0142] As shown in Table 3, the mixed powder obtained by using arginine instead of the specific component (Comparative Example 4) has an alkaline liquid property when dissolved in water. In addition, from the comparison of Example 1, Example 15, Example 29, and Comparative Examples 3 to 4 (comparison between the modes with different types of the second component only), it can be seen that the mixed powders (Example 1, Example 15, and Example 29) obtained by using a component other than the specific component as the second component show more excellent solubility than the mixed powders (Comparative Examples 3 to 4) obtained by using a component other than the specific component as the second component.
[0143] [Examples 1 to 14 (specific ingredient: tryptophan)]
[0144] From the comparison between Examples 1 to 3 and Examples 9 to 11 (comparison between the drying methods using an evaporator), it can be seen that the mixed powders obtained by Examples 1 to 3 using heating for dissolution tend to show more excellent solubility.
[0145] From the comparison of Examples 1 to 3 (comparison between methods with different mixing ratios only), it can be seen that the mixed powders obtained by Example 1 and Example 3 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 4 to 6 (comparison between methods with different mixing ratios only), it can be seen that the mixed powders obtained by Example 4 and Example 6 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 9 to 11 (comparison between methods with different mixing ratios only), it can be seen that Examples 9 to 10 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 12 to 14 (comparison between methods with different mixing ratios only), it can be seen that Examples 12 to 13 with a mixing ratio of 2 or more show more excellent solubility.
[0146] From the comparison of Example 1, Example 4, and Example 7 (comparison between methods with different drying methods only), it can be seen that the mixed powder obtained by Example 1 using an evaporator (heating and decompression) in drying and Example 4 using spray drying showed more excellent solubility. Among them, Example 4 using spray drying in drying showed further excellent solubility. Similarly, from the comparison of Example 3 and Example 6 (comparison between methods with different drying methods only), it can be seen that Example 6 using spray drying in drying showed more excellent solubility.
[0147] [Examples 15 to 28 (specific ingredient: serine)]
[0148] From the comparison between Examples 15 to 17 and Examples 23 to 25 (comparison between the drying methods using an evaporator), it can be seen that the mixed powders obtained by Examples 15 to 17 using heating for dissolution tend to show more excellent solubility.
[0149] From the comparison of Examples 15 to 17 (comparison between methods with different mixing ratios only), it can be seen that the mixed powders obtained by Examples 15 and 17 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 18 to 20 (comparison between methods with different mixing ratios only), it can be seen that the mixed powders obtained by Examples 18 and 20 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 23 to 25 (comparison between methods with different mixing ratios only), it can be seen that Examples 23 to 24 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 26 to 28 (comparison between methods with different mixing ratios only), it can be seen that Examples 26 to 27 with a mixing ratio of 2 or more show more excellent solubility.
[0150] From the comparison of Example 15, Example 18, and Example 21 (comparison between methods with different drying methods only), it can be seen that the mixed powder obtained by Example 15 using an evaporator (heating and decompression) in drying and Example 18 using spray drying showed more excellent solubility. Among them, Example 18 using spray drying in drying showed further excellent solubility. Similarly, from the comparison of Example 17 and Example 20 (comparison between methods with different drying methods only), it can be seen that Example 20 using spray drying in drying showed more excellent solubility.
[0151] [Examples 29 to 42 (specific component: threonine)]
[0152] From the comparison between Examples 29 to 31 and Examples 37 to 39 (comparison between the drying methods using an evaporator), it can be seen that the mixed powders obtained by Examples 29 to 31 using heating for dissolution tend to show more excellent solubility.
[0153] From the comparison of Examples 29 to 31 (comparison between methods with different mixing ratios only), it can be seen that the mixed powders obtained by Examples 29 and 31 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 32 to 34 (comparison between methods with different mixing ratios only), it can be seen that the mixed powders obtained by Examples 32 and 34 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 37 to 39 (comparison between methods with different mixing ratios only), it can be seen that Examples 37 to 38 with a mixing ratio of 2 or more show more excellent solubility. Similarly, from the comparison of Examples 40 to 42 (comparison between methods with different mixing ratios only), it can be seen that Examples 40 to 41 with a mixing ratio of 2 or more show more excellent solubility.
[0154] From the comparison of Example 29, Example 32, and Example 35 (comparison between methods with different drying methods only), it can be seen that the mixed powder obtained by Example 29 using an evaporator (heating and decompression) in drying and Example 32 using spray drying showed more excellent solubility. Among them, Example 32 using spray drying in drying showed further excellent solubility. Similarly, from the comparison of Example 31 and Example 34 (comparison between methods with different drying methods only), it can be seen that Example 34 using spray drying in drying showed more excellent solubility.
[0155] The solubility of the mixed powder obtained by the manufacturing method of the present invention when applied to E-MEM medium (Eagle's minimum essential medium) was evaluated as follows. Since the dissolution rate of cystine in the molecular mixed powder of the present invention containing cystine and at least one specific component selected from the group consisting of tryptophan, threonine and serine is extremely fast, it can be said that whether it is a medium containing the molecular mixed powder of cystine and the specific component of the present invention can be detected by the method shown below.
[0156] As a culture medium, a mixed powder obtained by mixing E-MEM culture medium B without cystine, tryptophan, threonine and serine as shown in Table 4 was uniformly mixed in a mortar to obtain a mixed powder of E-MEM culture medium B. E-MEM culture medium B was dissolved in water at a concentration of 12.0 g / L to obtain a culture medium liquid.
[0157] [Table 4]
[0158]
[0159] Using the thus prepared E-MEM medium B, as shown in Table 5, as Example 43, a medium B1 was prepared in which 0.15 g / L of the cystine / threonine = 1 / 4 (mass ratio) molecular mixed powder of the present invention was added to the EMEM medium B as cystine, and as Comparative Example 5, a medium B2 was prepared in which the cystine and threonine equivalent to the same amount were added to the EMEM medium B instead of the cystine / threonine molecular mixed powder used in Example 43. The same was performed for serine and tryptophan to obtain B3, B4, B5, and B6, respectively.
[0160] At room temperature 22 ° C, medium B1, medium B2 and a stirring rod were added to a 100 mL container, water was added to make it 50 mL, the time of adding water was set to 0 minutes, stirring was started at 100 rpm, and 1 mL was taken out from the slurry after 7 minutes. The slurry taken out was immediately filtered with a 0.2 μm filter to obtain liquids BL1 and BL2 respectively. The results of the cystine content of liquids BL1 and BL2 were measured by HPLC (high-speed liquid chromatography). The cystine content of BL1 was 0.15 g / L, and the cystine content of BL2 was 0.09 g / L. For B3, B4, B5, and B6, the same was performed to obtain liquids BL3, BL4, BL5, and BL6, and the cystine content was 0.15, 0.09, 0.15, and 0.09 g / L, respectively. The pH of the slurry before taking out was an acidity of 4 or more and less than 6.
[0161] In this example, the initial cystine addition amount was added at a concentration of 0.15 g / L close to the upper limit of the solubility, but in fact, it may not be added to the upper limit as the addition amount, and in the case of adding cystine and the powder of the specific component separately, even if the error is taken into account, the amount of cystine detected after 7 minutes will not exceed 0.12 g / L. Therefore, if the filtered liquid taken out after 7 minutes exceeds 0.12 g / L, it can be considered that the cystine mixed powder of the present invention is contained. The cystine concentration is preferably 0.12 g / L or more and 0.5 g / L or less, more preferably 0.13 g / L or more and 0.4 g / L or less, and most preferably 0.15 g / L or more and 0.3 g / L or less.
[0162] [Table 5]
[0163]
Claims
1. A method for producing a mixed powder, comprising the following steps: a dissolving step of dissolving cystine and at least one specific component selected from the group consisting of tryptophan, threonine, and serine in a solvent to obtain a solution containing cystine and the specific component; and The powdering step is to obtain a mixed powder of cystine and the specific component by drying the solution.
2. The method for producing a mixed powder according to claim 1, wherein: In the dissolving step, heating and / or alkali are used for dissolving.
3. The method for producing a mixed powder according to claim 1, wherein: In the dissolving step, heating is used for dissolving.
4. The method for producing a mixed powder according to claim 1, wherein: The powdering step is a step of drying the solution by spray drying and / or a step of drying the solution by heating and reducing pressure.
5. The method for producing a mixed powder according to claim 1, wherein: In the dissolving step, the mixing ratio of the specific component to cystine is 1 to 10 in terms of mass ratio. A mixed powder produced by the method for producing a mixed powder according to claim 1.
7. A mixed powder comprising cystine and at least one specific component selected from the group consisting of tryptophan, threonine and serine, wherein: When dissolved in water at 15 to 25°C for 7 minutes, the pH of the resulting solution is 6.0 to 8.5, and the cystine concentration in the resulting solution is 0.12 g / L or more.
8. A powder comprising cystine and at least one specific component selected from the group consisting of tryptophan, threonine and serine, wherein: When dissolved in water, the following conditions are met so that the final concentration of cystine becomes 0.14 g / L or more when completely dissolved at 15 to 25°C. Conditions: The time for adding water in an amount sufficient to achieve the final concentration was set to 0 minutes, and the liquid was taken out after 7 minutes and filtered through a 0.2 μm filter. The pH of the liquid was 8.5 or less, and the cystine contained was 0.12 g / L or more.
9. A powder culture medium comprising the mixed powder or powder according to any one of claims 6 to 8.
